A pilot feasibility study of TNFerade    biologic with XXXX and radiation therapy followed by surgical resection for the treatment of @entity5 .

@entity1 @entity137 @entity416 @entity5 @entity16178 @entity16065
OBJECTIVE: The purpose of this pilot study was to evaluate the feasibility and tolerability of weekly intratumoral TNFerade    injections combined with concurrent @entity416 and radiotherapy in the treatment of @entity1 with locally advanced @entity5 . METHODS: @entity1 with T3, T4, or N+ @entity5 received radiotherapy to a total dose of 50.4-54 Gy in combination with @entity416 937.5 mg/m(2) p.o. b.i.d. TNFerade    at a dose of 4 * 10(10) particle units was injected into the @entity5 on the first day of radiotherapy and weekly for a total of 5 injections. Surgery was performed 5-10 weeks after the completion of chemoradiation. RESULTS: Nine @entity1 were enrolled in this pilot trial. The stage was @entity16065 in 2 @entity1 , @entity16178 in 6 @entity1 , cT4 in 1 @entity1 , N- in 7 @entity1 and N+ in 2 @entity1 . Eight @entity1 completed all treatments. Grade 3 hematologic @entity137 was observed in 2 @entity1 . There was no @entity137 directly attributable to the injection procedure. A complete pathologic response was observed in 2 of 9 @entity1 . CONCLUSIONS: This study demonstrates the feasibility of weekly intratumoral TNFerade    injections during chemoradiotherapy for locally advanced @entity5 . Pathologic responses with this combination compare favorably to published rates.
